Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Propensity score-matched analysis supports the survival benefits of combination chimeric antigen receptor T-cell therapy with autologous transplantation in relapsed or refractory B-cell non-Hodgkin lymphoma: Insights from a real-world study in China

View Full Paper
Ask AI
Bookmark
Share

Authors

LHLongfei He

Discussion

Loading...

Member takes

Overview

Observational analysis shows enhanced overall and progression-free survival in refractory B-cell lymphoma, indicating CAR-T plus autologous stem cell benefits.

Key Points

  • Survival rates improved in patients receiving autologous transplantation with CAR-T therapy.
  • The objective response rate was 86.90% for ASCT+CAR-T compared to 72.18% for CAR-T alone.
  • Observational study analyzed 217 patients, utilizing 1:1 propensity score matching to control confounding factors.
  • Results emphasize the potential benefits of combining ASCT with CAR-T therapy for relapsed B-cell non-Hodgkin lymphoma.

Cite This Study

Longfei He (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df60https://doi.org/10.1182/blood-2025-3725
View Full Paper
Ask AI
Bookmark
Share